tetradecanoylphorbol acetate has been researched along with fraxetin in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kimura, Y; Sumiyoshi, M | 1 |
1 other study(ies) available for tetradecanoylphorbol acetate and fraxetin
| Article | Year |
|---|---|
Antitumor and antimetastatic actions of dihydroxycoumarins (esculetin or fraxetin) through the inhibition of M2 macrophage differentiation in tumor-associated macrophages and/or G1 arrest in tumor cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Body Weight; Cell Differentiation; Cell Line, Tumor; Cell Polarity; Cell Proliferation; Chemokine CCL2; Coumarins; Cyclin-Dependent Kinase 4; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Interleukin-10; Macrophage Activation; Macrophages; Male; Matrix Metalloproteinase 2; Mice; Neoplasm Metastasis; Osteosarcoma; STAT3 Transcription Factor; Tetradecanoylphorbol Acetate; Transforming Growth Factor beta1; Umbelliferones; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2015 |